TENAYA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.515 USD | +4.76% |
|
+0.90% | +37.96% |
| Mar. 20 | Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating | MT |
| Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 782.3 | 128.6 | 220.7 | 338.4 | - | - |
| Enterprise Value (EV) 1 | 531 | -75.61 | 116 | 275 | 286.4 | 330.4 |
| P/E ratio | -4.62 x | -0.73 x | -1.93 x | -2.49 x | -2.43 x | -2.54 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 406 x | 73.6 x | 8.28 x |
| EV / Revenue | - | - | - | 330 x | 62.3 x | 8.09 x |
| EV / EBITDA | -7.94 x | 0.63 x | -0.95 x | -1.93 x | -1.53 x | -1.59 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 2.81 x | 0.55 x | 1.71 x | 3.95 x | 8.13 x | 39.2 x |
| Nbr of stocks (in thousands) | 41,281 | 63,988 | 68,111 | 78,518 | - | - |
| Reference price 2 | 18.95 | 2.010 | 3.240 | 4.310 | 4.310 | 4.310 |
| Announcement Date | 3/23/22 | 3/8/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 0.8333 | 4.6 | 40.85 |
| EBITDA 1 | -66.9 | -119.2 | -122.5 | -142.5 | -187.4 | -208.4 |
| EBIT 1 | -72.81 | -125.6 | -131.2 | -139 | -166.5 | -173.2 |
| Operating Margin | - | - | - | -16,680.69% | -3,620.34% | -424.05% |
| Earnings before Tax (EBT) 1 | -72.72 | -123.7 | -124.1 | -133.4 | -151.4 | -154.6 |
| Net income 1 | -72.72 | -123.7 | -124.1 | -136.5 | -150.8 | -150.9 |
| Net margin | - | - | - | -16,376.44% | -3,278.92% | -369.46% |
| EPS 2 | -4.100 | -2.760 | -1.680 | -1.728 | -1.774 | -1.698 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/23/22 | 3/8/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.8333 | - |
| EBITDA 1 | - | - | - | -28.62 | -29.21 | -32.43 | -31.59 | -35.1 | -28.74 | -29.26 | -32.8 | -34.3 | -36.5 | -33.4 | - |
| EBIT 1 | -18.3 | -26.16 | -31.15 | -28.62 | -31.3 | -34.55 | -33.72 | -35.1 | -30.92 | -31.45 | -32.08 | -33.36 | -35.45 | -39.04 | -40.94 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | -4,684.94% | - |
| Earnings before Tax (EBT) 1 | -18.26 | -26.15 | -31.06 | -28.4 | -30.7 | -33.52 | -31.74 | -33.27 | -29.14 | -29.94 | -32.12 | -33.47 | -35.6 | -36.93 | -40.94 |
| Net income 1 | -18.26 | -26.15 | -31.06 | -28.4 | -30.7 | -33.52 | -31.74 | -33.27 | -29.14 | -29.94 | -33.38 | -34.4 | -35.99 | -36.99 | -40.94 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | -4,438.58% | - |
| EPS 2 | -0.6800 | -0.6300 | -0.7500 | -0.6900 | -0.7400 | -0.6100 | -0.4300 | -0.4500 | -0.3900 | -0.4000 | -0.4217 | -0.4300 | -0.4350 | -0.4450 | -0.5400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/23/22 | 5/11/22 | 8/10/22 | 11/10/22 | 3/8/23 | 5/10/23 | 8/9/23 | 11/8/23 | 3/18/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 251 | 204 | 105 | 63.4 | 52.1 | 8.02 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -47.4% | -64.8% | -126% | -260% | -577% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | 6.750 | 3.640 | 1.890 | 1.090 | 0.5300 | 0.1100 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 20.6 | 1.24 | 0.8 | 0.8 | 0.8 |
| Capex / Sales | - | - | - | 96% | 17.39% | 1.96% |
| Announcement Date | 3/23/22 | 3/8/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.31
USD
Average target price
19.43
USD
Spread / Average Target
+350.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.96% | 338M | |
| +2.55% | 42.75B | |
| +47.75% | 41.61B | |
| +12.38% | 41.34B | |
| -12.36% | 26.59B | |
| +8.36% | 25.49B | |
| -23.33% | 18.12B | |
| +30.65% | 12.24B | |
| -1.90% | 11.76B | |
| +7.53% | 11B |
- Stock Market
- Equities
- TNYA Stock
- Financials Tenaya Therapeutics, Inc.
